Carbinoxamine Maleate 4 Mg Oral Tablet
DESCRIPTION
Carbinoxamine maleate is a histamine-H1 receptor blocking agent.
Each tablet contains 4 mg carbinoxamine maleate and the following inactive ingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.
Carbinoxamine maleate is freely soluble in water. Its structure is:
2-[(4-chlorophenyl)-2-pyridinylmethoxy]- N, N- dimethylethanamine(Z)-2-butenedioate (1:1)
C
16H
19CIN
2O•C
4H
4O
4
MW=406.86
CLINICAL PHARMACOLOGY
Mechanism of Actions
Pharmacokinetics and Metabolism
In a study comparing a controlled-release suspension and a solution of carbinoxamine, healthy volunteers were administered a single dose of 8 mg carbinoxamine. A time to maximum concentration (Tmax) was between 1.5 hours to 5 hours, a peak plasma concentration (Cmax) of about 24 ng/mL was observed, and extent of exposure (AUC) was about 286 ng hr/mL. The serum half-life is reported to be 10 to 20 hours.
Drug/Food Interactions
Cardiovascular Effects
Special Populations
Carbinoxamine should not be used in newborn or premature infants. Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.
Pregnancy and Lactation
Safe use of carbinoxamine during pregnancy has not been established. Therefore, carbinoxamine should not be used in women who are, or may become pregnant. Carbinoxamine is in the FDA pregnancy Category C.
Women who are breastfeeding should avoid use of carbinoxamine, since small amounts appear to be distributed into breast milk.
Geriatric Patients
Carbinoxamine is more likely to cause dizziness, sedation, and hypotension in elderly patients. The incidence of adverse reactions is higher in the elderly; therefore, a dosing adjustment may be necessary in this sub-population.
INDICATIONS AND USAGE
Seasonal and perennial allergic rhinitis.
Vasomotor rhinitis.
Allergic conjunctivitis due to inhalant allergens and foods.
Mild, uncomplicated allergic skin manifestations of urticaria and angio-edema.
Dermatographism.
As therapy for anaphylactic reactions adjunctiveto epinephrine and other standard measures after the acute manifestations have been controlled.
Amelioration of the severity of allergic reactions to blood or plasma.
CONTRAINDICATIONS
Carbinoxamine maleate is contraindicated in nursing mothers.
Carbinoxamine maleate is contraindicated in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor therapy. (See Drug Interactions section).
WARNINGS
Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenald obstruction.
PRECAUTIONS
General
Antihistamines such as carbinoxamine maleate should not be used to treat lower respiratory tract symptoms, including asthma.
Information for Patients
Drug Interactions
Carbinoxamine maleate has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).
Carcinogenesis, Mutagenesis, Impairment of Fertility
Pregnancy
Pregnancy Category C:
Animal reproductive studies have not been conducted with carbinoxamine maleate. It is also not known whether carbinoxamine maleate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Carbinoxamine maleate should be given to a pregnant woman only if clearly needed.
Nursing Mothers
Pediatric Use
Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.
Carbinoxamine maleate may diminish mental alertness in children. In the young child, particularly, they may produce excitation.
Geriatric Use
ADVERSE REACTIONS
Body as a Whole:Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.
Cardiovascular:Hypotension, headache, palpitations, tachycardia, extrasystoles.
Hematologic:Hemolytic anemia, thrombocytopenia, agranulocytosis.
Central Nervous System: Sedation, sleepiness, dizziness, disturbed coordination,fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
Gastrointestinal: Epigastric distress,anorexia, nausea, vomiting, diarrhea, constipation.
Urogenital:Urinary frequency, difficult urination, urinary retention, early menses.
Respiratory: Thickening of bronchial secretions,tightness of chest and wheezing, nasal stuffiness.
OVERDOSAGE
Especially in infants and children, antihistamine overdosage may cause hallucinations, convulsions, or death.
DOSAGE AND ADMINISTRATION
Carbinoxamine maleate should be taken on an empty stomach with water.
DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.
Carbinoxamine maleate dosage should bebased on the severity of the condition and the response of the patient. The drug is well tolerated in adults in doses as high as 24 mg daily, in divided doses, over prolonged periods. On the other hand, some patients respond to as little as 4 mg daily.
Clinical experience suggests the followingdosage schedules:
Tablets
Usual Adult Dosage:
1 or 2 tablets (4 to 8 mg)
3 to 4 times daily.
Usual Child’s Dosage:
Six to eleven years – ½ to 1 tablet
(2 to 4 mg) 3 to 4 times daily.
HOW SUPPLIED
Carbinoxamine Maleate Tablets, USP 4 mg are supplied as white, round, scored tablets, debossed "CM" on one side and scored on the other, and supplied in bottles of 100 tablets, NDC44523-825-01.
Store at 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature.]
Dispense in a tight, light-resistant container with a child-resistant closure as defined in the official compendium.
ASK A DOCTOR